Mereo to develop Etigilimab (Anti-TIGIT) alongside rare disease product portfolio after completing $70M private placement
Mereo BioPharma on Thursday announced the completion of a $70 million (£56 million) private placement (the “Fundraising”) with a number of new and existing U.S based institutional and accredited investors.